Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, Simon 2-stage, phase 2 clinical study conducted in subjects with
advanced or metastatic colorectal cancer who have previously received ≥ 1 prior line of
systemic therapies and are resistant to EGFR inhibitor (cetuximab or panitumumab).
This trial will be conducted to determine objective response rate (ORR), progression-free
survival (PFS) and overall-survival (OS) of cetuximab plus tivantinib in patients with
wild-type KRAS CRC that is resistant to anti-EGFR antibody treatment (cetuximab or
panitumumab) and shows overexpression of cMET.